Publication Name	World Journal of Clinical Cases
Manuscript ID	76518
Country	Greece

Received	2022-03-20 10:19
Peer-Review Started	2022-03-20 10:21
To Make the First Decision
Return for Revision	2022-04-28 05:23
Revised	2022-05-20 02:23
Second Decision	2022-07-08 02:52
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2022-07-11 18:45
Articles in Press	2022-07-11 18:45
Publication Fee Transferred
Edit the Manuscript by Language Editor	2022-07-05 09:22
Typeset the Manuscript	2022-07-18 01:51
Publish the Manuscript Online	2022-08-01 09:20

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Letter to the Editor
Article Title	Comment on “Disease exacerbation is common in inflammatory bowel disease patients treated with immune checkpoint inhibitors for malignancy”
Manuscript Source	Unsolicited Manuscript
All Author List	Konstantinos Argyriou and Athanasios Kotsakis
ORCID	Author(s) ORCID Number Konstantinos Argyriou http://orcid.org/0000-0002-2026-9678
Funding Agency and Grant Number
Corresponding Author	Konstantinos Argyriou, MD, MSc, PhD, Academic Fellow, Consultant Physician-Scientist, Department of Gastroenterology, University Hospital of Larisa, Mezourlo, Larisa GR41334, Greece. kosnar2@doctors.org.uk
Key Words	Inflammatory bowel disease; Immune-related adverse events; Immune checkpoint inhibitors; Immunotherapy; Malignancy
Core Tip	Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment due to their ability to empower patients’ anti-neoplastic immune response. However, by empowering the immune system, ICIs can trigger off-site inflammation and autoimmunity, raising safety concerns every time these agents are considered for cancer patients with pre-existing autoimmune disorders such as inflammatory bowel disease (IBD). In this article, Samuel Rubin et al investigated how immunotherapy affects pre-existing enteral disease in a cohort of IBD patients on ICIs; however, we detected several limitations that need further consideration. Therefore, we would like to share our views on this interesting study.
Publish Date	2022-08-01 09:20
Citation	Argyriou K, Kotsakis A. Comment on “Disease exacerbation is common in inflammatory bowel disease patients treated with immune checkpoint inhibitors for malignancy”. World J Clin Cases 2022; 10(23): 8425-8427
URL	https://www.wjgnet.com/2307-8960/full/v10/i23/8425.htm
DOI	https://dx.doi.org/10.12998/wjcc.v10.i23.8425

Full Article (PDF)	WJCC-10-8425.pdf
Full Article (Word)	WJCC-10-8425.docx
Manuscript File	76518_Auto_Edited-YJM-Webster J-LS.docx
Answering Reviewers	76518-Answering reviewers.pdf
Audio Core Tip	76518-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	76518-Conflict-of-interest statement.pdf
Copyright License Agreement	76518-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	76518-Language certificate.pdf
Peer-review Report	76518-Peer-review(s.pdf
Scientific Misconduct Check	76518-Bing-Ma YJ-2.png
Scientific Editor Work List	76518-Scientific editor work list.pdf
CrossCheck Report	76518-CrossCheck Report.pdf